急性和慢性tepoxalin对肾功能的影响在狗与慢性肾脏疾病和骨关节炎。

文章的细节

引用

复制到剪贴板

洛玛斯,里昂SD,桑德森兆瓦,劳尔的女朋友

急性和慢性tepoxalin对肾功能的影响在狗与慢性肾脏疾病和骨关节炎。

J兽医研究》2013年6月,74 (6):939 - 44。doi: 10.2460 / ajvr.74.6.939。

PubMed ID

23718664 (在PubMed

]

文摘

目的:确定tepoxalin肾功能改变与慢性肾脏疾病(CKD)的狗。动物:16只狗与慢性肾病(国际肾脏利益社会阶段2或3)和骨关节炎。程序:肾功能评估通过血清生化分析,验尿,尿protein-to-creatinine集中度,尿液gamma-glutamyl transpeptidase-to-creatinine集中度,受者等离子体间隙,和间接血压测量两次治疗。狗收到tepoxalin(10毫克/公斤,阿宝,q 24 h) 28天(急性期;n = 16)和一个附加的6个月(慢性阶段;10)。复核检查每周(急性期)和1、3和6个月(慢性阶段)。肾功能的变量进行了分析通过重复测量方差分析。结果:没有任何变量的差异随着时间的推移,狗完成这项研究的两个阶段。医疗药品不良事件导致中止tepoxalin管理包括增加血清肌酐浓度(1狗; week 1), collapse (1 dog; week 1), increased liver enzyme activities (1 dog; week 4), vomiting and diarrhea (1 dog; week 8), hematochezia (1 dog; week 24), and gastrointestinal ulceration or perforation (1 dog; week 26). Preexisting medical conditions and concomitant drug use may have contributed to ADEs. Kidney function was not affected in the latter 5 dogs. Discontinuation of tepoxalin administration stabilized kidney function in the former dog and resolved the ADEs in 4 of the 5 latter dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Tepoxalin may be used, with appropriate monitoring, in dogs with International Renal Interest Society stage 2 or 3 CKD and osteoarthritis.

DrugBank数据引用了这篇文章

药物

Tepoxalin